New screening platform for ONTs? Pharmaron’s LC-MS-based lysosome stability assay offers a predictive drug development screening platform for evaluating oligonucleotide degradation and resistance. Supporting smarter therapeutic development. Presented at #ISSX2025, download the poster using the link in the first comment. #siRNA #DrugDesign #PharmaronDMPK
关于我们
Pharmaron: Global Life Sciences Services Provider Stock Code: 300759.SZ/3759.HK Founded in 2004, Pharmaron is a premier life sciences service provider that offers a broad spectrum of research, development, and manufacturing service capabilities throughout the entire drug discovery, preclinical, and clinical development process across multiple therapeutic modalities, including small molecules, biologics, and CGT products. Pharmaron’s Comprehensive CRO & CDMO Services • Synthetic, Medicinal, and Analytical Chemistry Services • Biology Services (e.g., in vitro screening, structural biology, biomarkers) • DMPK Services (e.g., in vitro ADME, in vivo PK, PKPD, mass balance) • Pharmacology Services (e.g., in vivo pharmacology, animal disease models, immunotoxicity) • Drug Safety Assessment Services (e.g., toxicology, safety pharmacology, genetic toxicology) • Radiochemistry and Isotopically Labelled Metabolism Services (e.g., 14C/Carbon-14 radiosynthesis, 3H/tritium radiosynthesis, QWBA, mARG) • CMC Services (e.g., API manufacturing, process chemistry, formulation development) • Clinical Development Services (e.g., First-in-Human [FIH], ethnobridging, microdosing Phase 0, absolute bioavailability) Commitment to Excellence and Innovation With a proven track record of success, Pharmaron continually invests in its people, facilities, and technologies to meet evolving scientific and regulatory demands. The company prides itself on enabling scientific breakthroughs and supporting its partners in advancing human health. ____________________________________ Learn More: Explore Pharmaron’s services to discover how to accelerate your R&D programs. www.pharmaron.com. ________________________________________ Keywords: CRO, CDMO, synthetic chemistry, medicinal chemistry, biology, radiochemistry, toxicology, First-in-Human, API manufacturing, PKPD, 14C radiosynthesis, discovery biologics, clinical development, small molecules, biologics, cell and gene therapy (CGT) products
- 网站
-
http://www.pharmaron.com
Pharmaron的外部链接
- 所属行业
- 制药业
- 规模
- 超过 10,001 人
- 总部
- Beijing
- 类型
- 私人持股
- 创立
- 2004
- 领域
- Chemistry、Biology、DMPK、Pharmacology、Chemical Development、Preclinical、Toxicology、Safety Pharmacology、Discovery、Lead Optimization、Process Development、Assay Development、ADME、Formulation、clinical pharmacology、analytical sciences、radiolabelled chemistry、accelerator mass spectrometry、radiolabelled compounds、API manufacturing、radiosynthesis、Biologics、CGT 、cell and gene therapy、synthetic chemistry、medicinal chemistry、radiochemistry、PKPD和small molecule
地点
Pharmaron员工
动态
-
At Pharmaron, our 𝐎𝐜𝐮𝐥𝐚𝐫 𝐝𝐢𝐬𝐞𝐚𝐬𝐞 𝐦𝐨𝐝𝐞𝐥𝐬 help advance ophthalmic therapies by evaluating efficacy in clinically relevant disease models. We offer: > Validated models for glaucoma, dry eye, corneal injury & more > Multimodal imaging: OCT, ERG, slit-lamp, fundus photography > Precise dose routes: intravitreal, subretinal, topical, suprachoroidal > Expert oversight from board-certified ophthalmologists & veterinarians Our studies are conducted in a 𝐆𝐋𝐏-𝐜𝐨𝐦𝐩𝐥𝐢𝐚𝐧𝐭, 𝐀𝐀𝐀𝐋𝐀𝐂-𝐚𝐜𝐜𝐫𝐞𝐝𝐢𝐭𝐞𝐝 facility with full support from surgical and imaging technologies—ensuring robust, reproducible data for both anterior and posterior segment indications. Whether you're developing small molecules, biologics, or gene therapies, Pharmaron provides the 𝐬𝐜𝐢𝐞𝐧𝐭𝐢𝐟𝐢𝐜 𝐫𝐢𝐠𝐨𝐫 𝐚𝐧𝐝 𝐭𝐫𝐚𝐧𝐬𝐥𝐚𝐭𝐢𝐨𝐧𝐚𝐥 𝐦𝐨𝐝𝐞𝐥𝐬 to move your program forward. Learn more below! #Ophthalmology #InVivoPharmacology #DrugEfficacy #Pharmaron #PreclinicalResearch #GeneTherapy #Biologics #OcularModels #ImagingTech #GLP
-
-
Struggling with unpredictable preclinical results due to a lack of clinically relevant Alzheimer’s mouse models? Selecting the most suitable transgenic Alzheimer’s mouse model is a critical step to ensure the translatability of preclinical findings, as it directly impacts the predictive power and success of your studies. Our latest study compares two widely used Aβ-driven models, APP/PS1 and 5xFAD, characterizing age-related cognitive decline, Aβ pathology, and transcriptomic signatures across both to guide smarter, mechanism-aligned model selection and help our clients make informed strategic decisions for their drug discovery programs. The study emphasizes the importance of: • Selecting appropriate preclinical models for early-stage vs. long-term studies • Mechanism of Action-aligned drug screening of your compound on clinically relevant mouse models • Ways to reduce translational risk and strengthen overall study design #AlzheimersResearch #TranslationalScience #PreclinicalModels #DrugDiscovery #Neuroscience
-
What makes a method transfer successful? According to many of the discussions at 𝐉𝐏𝐀𝐆 𝟐𝟎𝟐𝟔, it's often the knowledge behind the method—not just the method itself. Colleagues from both our Cramlington and Hoddesdon sites attended the conference, where Anna Zhalnina, Alice H., Neve Bentley and Natalie Hunter-Dost presented scientific posters and shared expertise in analytical method validation and transfer. A key takeaway was the importance of 𝐤𝐧𝐨𝐰𝐥𝐞𝐝𝐠𝐞 𝐭𝐫𝐚𝐧𝐬𝐟𝐞𝐫 𝐚𝐥𝐨𝐧𝐠𝐬𝐢𝐝𝐞 𝐦𝐞𝐭𝐡𝐨𝐝 𝐭𝐫𝐚𝐧𝐬𝐟𝐞𝐫. Small, experience-based details can make all the difference when it comes to successful transfers and efficient troubleshooting. Thank you to everyone who shared their insights and experiences. Our team returned with valuable learnings and ideas to take forward. Interested in learning more about the analytical capabilities at our Cramlington site? Get in touch with our team or visit our website. https://lnkd.in/eviY8aJc #JPAG2026 #AnalyticalScience #MethodValidation #Pharmaron
-
-
Bone repair, joint stabilization, regenerative integration—orthopedic devices face complex demands. Pharmaron offers tailored preclinical models to test: > Plating systems > Interlocking nails > Stem cell therapies and biomaterials We help developers meet safety and performance goals with data that supports clinical success. Partner with us to advance your orthopedic solution: https://lnkd.in/dmwPqq-E #Pharmaron #OrthopedicDevices #MobilityCare #PreclinicalTesting #ImplantableTech
-
-
Unlock the potential of AAV gene therapies with Pharmaron’s innovative platform. Using HTPD and DoE, we fine-tune parameters for optimal performance. Learn how our adaptable toolbox manages diverse AAV products and serotypes. Get the full details by downloading our poster: https://lnkd.in/dHq8sP8s #AAVgenetherapy #genetherapy #aav #Pharmaron #HTPD #DoE #Innovation
-
-
𝐃𝐫𝐢𝐯𝐢𝐧𝐠 𝐈𝐧𝐧𝐨𝐯𝐚𝐭𝐢𝐨𝐧 𝐓𝐡𝐫𝐨𝐮𝐠𝐡 𝐈𝐧𝐭𝐞𝐠𝐫𝐚𝐭𝐞𝐝 𝐃𝐫𝐮𝐠 𝐃𝐢𝐬𝐜𝐨𝐯𝐞𝐫𝐲 𝐚𝐧𝐝 𝐃𝐞𝐯𝐞𝐥𝐨𝐩𝐦𝐞𝐧𝐭 𝐚𝐭 𝐏𝐡𝐚𝐫𝐦𝐚𝐫𝐨𝐧 At Pharmaron, our co‑located Integrated Drug Discovery and Development (IDDD) team supports partners from 𝐡𝐢𝐭 𝐢𝐝𝐞𝐧𝐭𝐢𝐟𝐢𝐜𝐚𝐭𝐢𝐨𝐧 𝐭𝐡𝐫𝐨𝐮𝐠𝐡 𝐜𝐚𝐧𝐝𝐢𝐝𝐚𝐭𝐞 𝐬𝐞𝐥𝐞𝐜𝐭𝐢𝐨𝐧 𝐚𝐧𝐝 𝐨𝐧 𝐭𝐨 𝐈𝐍𝐃 𝐟𝐢𝐥𝐢𝐧𝐠. By bringing together world‑class scientific expertise with global resources, we deliver true end‑to‑end discovery support that accelerates the journey from idea to high‑quality drug candidate. Our capability is powered by expert teams across: ▪️Chemistry ▪️CADD ▪️DMPK ▪️Modelling ▪️Biology With a proven track record across multiple therapeutic areas and modalities, we provide the strategic insight, data‑driven decision‑making and coordinated project leadership needed to solve complex scientific challenges. From concept to IND, our teams work seamlessly together to help advance innovative therapeutics with speed and scientific rigor. 👉 Ready to take your discovery program further? Let’s explore how our IDDD team can accelerate your next breakthrough. Get in touch with us today. https://lnkd.in/drHkwiiV
-
-
From Discovery to NDA: Pharmaron’s DMPK strategy is built for every phase. Whether you're optimizing lead compounds or preparing for regulatory submission, our integrated DMPK services ensure milestone-ready data and reduced development risk. Global sites, local expertise in the UK, US and China. Explore our brochure using the link in the first comment, or scan the QR code. #DrugDevelopment #DMPK #Pharmaron #DMPKStrategy
-
-
Gene therapy is transforming ophthalmology, offering hope for conditions once considered untreatable. But moving from concept to clinic requires rigorous preclinical and CMC strategies to ensure safety, efficacy, and scalability. At Pharmaron, we explore: > Key considerations for ocular gene therapy development > Challenges in vector design and manufacturing > Regulatory expectations for preclinical studies Learn more below! What do you think will be the biggest breakthrough in ocular gene therapy over the next 5 years? Share your thoughts below!
-
-
Understanding how tumors escape therapy is critical to developing better treatments. In this in vivo CRISPR screen, over 3,100 sgRNAs targeting tumor suppressor genes were introduced into lung cancer A549 cells. These modified cells were engrafted into mice and treated with the MEK inhibitor Trametinib. By analyzing tumor tissues post-treatment, researchers identified gene disruptions that conferred resistance—revealing new survival pathways. Learn how Pharmaron supports oncology discovery through precision gene editing and deep sequencing. Link to download the full poster in the comments below. #CRISPR #OncologyResearch #DrugResistance #TumorBiology #Pharmaron
-